Published in Blood on June 15, 1998
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging (2004) 2.58
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001) 2.04
A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia (2009) 1.52
Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol (2009) 1.46
Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med (2012) 1.43
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging (2003) 1.35
Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging (2003) 1.34
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol (2009) 1.24
How to study optimal timing of PET/CT for monitoring of cancer treatment. Am J Nucl Med Mol Imaging (2011) 1.19
PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol (2006) 1.16
Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging (2007) 1.12
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging (2007) 1.10
FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol (2008) 1.03
Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica (2010) 1.03
Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging (2006) 0.98
Predictive and prognostic value of FDG-PET. Cancer Imaging (2008) 0.96
Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2003) 0.95
Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging (2003) 0.94
Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging (2006) 0.94
90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging (2005) 0.92
Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET. Eur J Nucl Med Mol Imaging (2008) 0.90
Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg (2001) 0.87
The role of SPET and PET in monitoring tumour response to therapy. Eur J Nucl Med Mol Imaging (2003) 0.84
The impact of functional imaging on radiation medicine. Radiat Oncol (2008) 0.84
Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging (2006) 0.83
Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. Radiology (2016) 0.81
Development of radiotracers for oncology--the interface with pharmacology. Br J Pharmacol (2011) 0.81
Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging (2003) 0.80
Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. Med Biol Eng Comput (2015) 0.79
Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values. Int J Clin Oncol (2009) 0.78
Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg (2003) 0.77
PET in lymphoma. Cancer Imaging (2006) 0.77
Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography. Adv Hematol (2010) 0.76
Investigation of dose minimisation protocol for 18F-FDG PET-CT in the management of lymphoma postchemotherapy followup. ScientificWorldJournal (2012) 0.76
In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937. Eur J Nucl Med Mol Imaging (2004) 0.75
The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. Cancer Med (2014) 0.75
Has PET become an important clinical tool in paediatric imaging? Eur J Nucl Med Mol Imaging (2004) 0.75
Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy. ScientificWorldJournal (2014) 0.75
FDG-PET imaging in hematological malignancies. Blood Rev (2016) 0.75
Shock-wave lithotripsy of gallbladder stones. The first 175 patients. N Engl J Med (1988) 5.53
Postmenopausal hormone therapy and mortality. N Engl J Med (1997) 4.96
Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med (1998) 3.73
Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med (2001) 3.39
Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res (1997) 3.36
Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med (1999) 3.20
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91
Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol (1994) 2.78
Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci U S A (1996) 2.77
Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med (1986) 2.76
Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science (1984) 2.75
The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature (1989) 2.75
Statement on the nomenclature of human C4 allotypes. Immunobiology (1983) 2.66
Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med (1986) 2.63
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol (2000) 2.60
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol (2000) 2.58
Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res (1998) 2.35
Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A (1991) 2.32
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol (1998) 2.22
Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet (1999) 2.21
Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. J Nucl Med (1991) 2.18
Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol (1992) 2.18
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation (2009) 2.15
Informatics and medicine--from molecules to populations. Methods Inf Med (2008) 2.13
Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med (2001) 2.12
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med (1999) 2.11
Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med (1991) 2.09
Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources. J Am Acad Child Adolesc Psychiatry (1999) 2.07
Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol (1990) 2.07
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001) 2.04
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology (2009) 1.99
Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry (1997) 1.96
Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med (1998) 1.96
Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med (1995) 1.95
Genetics of the apolipoprotein E system in man. Am J Hum Genet (1980) 1.94
A simple method for identifying the palindromic sequences recognized by restriction endonucleases: the nucleotide sequence of the AvaII site. Gene (1978) 1.91
Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol (1999) 1.86
Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood (1996) 1.85
Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain (2001) 1.83
Immunoaffinity purification of the epidermal growth factor receptor. Stoichiometry of binding and kinetics of self-phosphorylation. J Biol Chem (1984) 1.80
Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest (1981) 1.79
Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med (1996) 1.79
Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. J Am Coll Cardiol (1990) 1.73
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
The relationship between myocardial retention of technetium-99m teboroxime and myocardial blood flow. J Am Coll Cardiol (1992) 1.68
Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol (1997) 1.68
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol (2005) 1.67
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med (1999) 1.63
Inhibition of the G1-S transition of the cell cycle by inhibitors of deoxyhypusine hydroxylation. Biochim Biophys Acta (1994) 1.62
Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med (1997) 1.61
Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A (2009) 1.60
Effect of omega-3 fatty acids on growth of a rat mammary tumor. J Natl Cancer Inst (1984) 1.59
A pilot study of neuropsychological function in girls with ADHD. J Am Acad Child Adolesc Psychiatry (1997) 1.56
Ratio of myeloid and plasmacytoid dendritic cells and TH2 skew in CRS with nasal polyps. Allergy (2009) 1.55
Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg (1997) 1.53
Moderate patient-prosthesis mismatch after valve replacement for severe aortic stenosis has no impact on short-term and long-term mortality. Heart (2008) 1.52
Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1989) 1.51
Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol (2000) 1.49
The duration of antigen receptor signalling determines CD4+ versus CD8+ T-cell lineage fate. Nature (2000) 1.49
O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med (2000) 1.48
Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. J Am Coll Cardiol (1991) 1.48
Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography. Eur Heart J (2001) 1.47
Patient controlled analgesia for extracorporeal shock wave lithotripsy of gallstones. Pain (1992) 1.47
The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.46
Production of an epidermal growth factor receptor-related protein. Science (1984) 1.46
Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med (2000) 1.45
Psychiatric, neuropsychological, and psychosocial features of DSM-IV subtypes of attention-deficit/hyperactivity disorder: results from a clinically referred sample. J Am Acad Child Adolesc Psychiatry (1998) 1.45
[Metabolic products of microorganisms. 175. Tetracenomycin C (author's transl)]. Arch Microbiol (1979) 1.44
Region-specific encoding of sensory and affective components of pain in the human brain: a positron emission tomography correlation analysis. Ann Neurol (1999) 1.43
Focal metabolic activation in the predominant left auditory cortex in patients suffering from tinnitus: a PET study with [18F]deoxyglucose. ORL J Otorhinolaryngol Relat Spec (1997) 1.42
Determination of extent and location of coronary artery disease in patients without prior myocardial infarction by thallium-201 tomography with pharmacologic stress. J Nucl Med (1992) 1.41
Comparison of technetium-99m sestamibi and thallium-201 retention characteristics in canine myocardium. J Am Coll Cardiol (1992) 1.41
[Experimental ultrasound angioplasty: in vitro resolution of thrombi]. Z Kardiol (1995) 1.40
Correlation of work structure and job satisfaction among Israeli family physicians. Isr Med Assoc J (1999) 1.40
An automated analysis program for the evaluation of cardiac PET studies: initial results in the detection and localization of coronary artery disease using nitrogen-13-ammonia. J Nucl Med (1993) 1.39
Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging (2006) 1.39
Early recovery of coronary flow reserve after stent implantation as assessed by positron emission tomography. J Am Coll Cardiol (1999) 1.38